Methods and results
We analysed surveillance data collected by doctors (1999) (2000) and an anonymised national survey (1998) for cases of tuberculosis in London from 1998 to 2000. We calculated the delay in diagnosis as the number of days between the onset of symptoms and diagnosis or the start of treatment (which were on the same day in cases with both recorded). Delay was characterised as greater than the median or at or less than the median. We used unconditional logistic regression to investigate factors that were independently associated with delay.
A total of 1355 patients had a positive result in smear tests of pulmonary sputum; we give results for 853 (63%) about whom data on the time between onset of symptoms and diagnosis had been recorded.
Patients with data and those without were similar for age, sex, and ethnic group.
The 
Comment
Delay between the onset of symptoms of pulmonary tuberculosis and diagnosis or treatment (median 49 days) was more common for white people and for women. This median delay is similar to findings in other large cities in industrialised nations. 5 This might be because tuberculosis may be suspected and investigated more readily among men or black or Asian people.
Our study was limited by the amount of missing surveillance data. It was also impossible to determine the relative contribution of patient and healthcare provider to the total delay. Potential confounders-for example, coinfection with HIV or the accuracy of the data among patients whose first language was not English-were not taken account of.
Recent campaigns have tried to raise awareness of tuberculosis, particularly among ethnic minority groups. Our data suggest that campaigns also need to be targeted at white people, who comprise a third of cases. 
Drug points
Erythromelalgia induced by possible calcium channel blockade by ciclosporin
Erythromelalgia, a symptom complex of painful inflammatory vasodilatation of extremities, is usually idiopathic or due to thrombocythaemia. It has often been regarded as inverse Raynaud's phenomenon, rarely induced by calcium channel blockers. 1 We report a case of erythromelalgia induced by ciclosporin.
A 37 year old man had been taking ciclosporin 75 mg twice daily for psoriasis vulgaris for four weeks when he developed marked erythema, oedema, and tenderness over fingers and toes. Symptoms increased with warmth and were relieved partially with cold compresses. His full blood count, serum biochemistry, urine analysis, and collagen profile were normal. Erythromelalgia induced by ciclosporin was considered, and the drug was withdrawn. Lesions regressed within a week but recurred when ciclosporin was restarted. No recurrence was observed at one year follow up.
Erythromelalgia is a multifactorial peripheral vascular phenomenon akin to sympathectomy, with attenuation of vasomotor tone probably mediated through vasoactive substances and drugs such as nifedipine, nicardipine, verapamil, and bromocriptine. 1 Ciclosporin, a calcineurin antagonist, acts by inhibiting calcium-calmodulin signalling systems of target cells in a way similar to calcium channel blockers.
2 It binds to calmodulin, with a consequent inhibition of dephosphorylation of calmodulin induced kinases and other calmodulin dependent intracellular activities. 3 Ciclosporin also affects the calmodulin regulated activity of the actomyosin complex of smooth muscle of peripheral vessels, which leads to vasodilatation. In this way, ciclosporin has also been observed to potentiate the peripheral vasodialatory effects of calcium channel blockers. 4 The erythromelalgia in this patient may have been the result of ciclosporin acting in a similar way to calcium channel blockers. Though burning sensation of the hands and feet has been mentioned as an adverse effect in the product leaflet of ciclosporin (Panimun Bioral, Panacea Biotec) and a leg pain syndrome has been described, an erythromelalgia-like effect has not been reported. 5 This possible vasoactive effect of ciclosporin needs further evaluation given that vasoactive peptides may be present in psoriasis.
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